Member Info for crumbs

From out of a Ruck sack :)

We will also be paying polypeptide group for modi1 manufacturing

We do not know how much ISA are getting... was that a one off payment..I dunno

Yes, funds gonna be needed by H2 I'd say...

Yes...Karolinska seems to feature a lot and notice the TCR mentioned again in relation to them...fascinating we get to know so little though till months and months after lol...

'Scancell was pleased to extend its strategic research collaboration with the Rheumatology Unit at the Karolinska Institute, Sweden. The expanded agreement will explore the potential of the Moditope® platform to develop multiple immunotherapeutic agents for a range of different cancers. Scancell's research has shown that citrullinated proteins are involved in the control of tumour growth and we believe that this expanded collaboration will help us to further develop Moditope®, not only for use in cancer vaccines, but also other cancer immunotherapy approaches including T-cell receptor (TCR) based therapeutics which is also the subject of Scancell's research collaboration with BioNTech announced in January 2018.'

So that is very positive as is Modi2 developments:

Modi-2

Whilst Modi-1 acts by stimulating the production of CD4 T cells using citrullinated tumour-associated peptide epitopes, Modi-2 exploits a new modification, stimulating the production of cytotoxic CD4 T cells using homocitrullinated tumour-associated peptide epitopes. Whereas citrullination involves the conversion of the amino acid arginine to citrulline, the process of homocitrullination involves the conversion of lysine to homocitrulline. Scancell believes this second mechanism of action has the potential to broaden the utilisation of the Moditope® platform.

Modi-2 is currently in pre-clinical development and work is underway to characterise specific homocitrullinated peptides for clinical development that have the potential to address different cancer indications to Modi-1, including tumours with a PARTICULARLY IMMUNOSUPPRESSIVE environment.

What value that?
The data generated to date clearly demonstrates the potential of homocitrullinated, as well as citrullinated, tumour-associated peptide epitopes to be developed for the treatment of solid cancers.

Also sounds like a lot of work going on with modi2...I have no doubt Lindy and team will tweak that to a pre-clinical 100% survival too.. and seemingly it will be able to go into treating some very hard targets

With nothing, I can see that is new news standing out within them lol.... Apart from cash is burning

Interims out

You add 3 letters or 4 letters and one word and you get attention ..those are TCR/CAR T and Keytruda...that is just how it is at the moment in the emerging field of immuno oncology ....understandable as that is where the commercial acrion is at....in another 5 years it could be all different but scancell are playing the right tactics for the current game,

It's had, 729 viewers.... That's not bad by scancell terms I think we are attracting the interest of some of the cell therapy guys...intrigued by this whole TCR angel... but yes till a deal it is no deal till a trial it is no trial... but as Cliff says scancell have a strong bow and quite a few strong strings and arrows to shoot.... my feeling is the BioNtech collab is coming towards its conclusion I noticed in the PDF nana posted a link to yesterday the one from Calculus presentation had the BioNtech collab concluding H1 2019 well here we are and hiring a TCR specialist-why?... my other feeling is if we do get that first deal it will wake up not just AIM but all pharma/big bios who are into Immuno oncology... as in watch how they all want in... well with 2 possibly 3 platforms of multiple products and tens of cancer targets there are plenty of potential deals to be done... onwards! Come on FDA come on team scancell come on BioNtech and Genentech lol

'I give up this evening'

says it all

If you can't explain it simply, you don't understand it well enough.

A Einstein....

We probably get about 10 cancer is cured mass media headlines every year with nothing then heard from them.... its weird isnt it.. the one time Lindy hit the tabloids it was because she had actually 'cured' someone ,,,not a mouse but ever since seemingly blanked... sigh

BTW...moditope is being peer-reviewed in the lab by BioNtech...lets see what comes of that

I think the answers are in the article... hope your keeping well J53

'Still skepticism was high among those in the know. Weighing in on behalf of the American Cancer Society (ACS) on his blog, “A Cure For Cancer? Not So Fast,” Len Lichtenfeld, MD, ACS chief medical officer cautioned: “…it goes without saying, we all share the aspirational hope that they are correct. Unfortunately, we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure."

Lichtenfeld went on to list several key points that he says must be kept in mind no matter what media reports say:

This is a news report based on limited information provided by researchers and a company working on this technology. It apparently has not been published in the scientific literature where it would be subject to review, support and/or criticism from knowledgeable peers.'

Topsy turvy world...

Or maybe admin dreaded inanaco answering:)))

I thought the adding of the adjuvant was to make it practical.. as before the dose would have been very impractical ( I seem to remember Lindy referring to a vaccine manager having advised her on that) ... and that indeed Amplivant has brought with it added benefits and is a tech Lindy is very impressed with...so all good! We get there, in the end, same as with manufacturing niggles .

I thought the adding of the adjuvant was to make it practical.. as before the dose would have been very impractical ( I seem to remember Lindy referring to a vaccine manager having advised her on that) ... and that indeed Amplivant has brought with it added benefits and is a tech Lindy is very impressed with...so all good! We get there, in the end, same as with manufacturing niggles .

Beautiful is this... again we all know it needs to go through trials to be sure still.. that word 'naturally' it is why I'm in scancell and think they will be going places...

''One characteristic of cancer that makes it particularly difficult to treat is its capacity to induce immune suppression, creating a microenvironment within which it can hide. Moditope beats this NATURALLY, without the need for checkpoint inhibitors, which are dogged by concerns over side effects'
.